Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

By S. Wei, C. Duffy, James P. Allison. Cancer Discovery, 2018

2,514 citations recorded by the source corpus.

Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community to begin to envision potentially curative therapeutic approaches. However, the remarkable responses to immunotherapies are currently limited to a minority of patients and indications, highlighting the need for more effective and novel approaches. Indeed, an extraordinary amount of preclinical and clinical investigation is exploring the therapeutic potential of negative and positive costimulatory molecules. Insights into the underlying biological mechanisms and functions of these molecules have, however, lagged significantly behind. Such understanding will be essential for the rational design of next-generation immunotherapies. Here, we review the current state of our understanding of T-cell costimulatory mechanisms and checkpoint blockade, primarily of CTLA4 and PD-1, and highlight conceptual gaps in knowledge.Significance: This review provides an overview of immune checkpoint blockade therapy from a basic biology and immunologic perspective for the cancer research community. Cancer Discov; 8(9); 1069-86. ©2018 AACR.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/d55fdb93cb09f363fee0cb685822f734afff73c8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. J. Joyce
3. M. Locati
4. G. Curtale
5. Yan Yu
6. Weitong Gao
7. Yang Zhou
8. Xuepeng Wang

In Oncology

1. A. Mantovani
2. M. Locati
3. J. Joyce
4. A. Sica
5. Lisa M. Coussens
6. P. Allavena
7. S. Gordon
8. J. Pollard

Citations in the corpus

• Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy (2022, background): “Mechanically, ICIs inhibit cancer development by restoring the function of effector T cells.(17,19) Traditionally, it was believed that immunotherapyactivated CD8+ T cells induce tumor cell death mainly through the perforin-granzyme pathway and the Fas-Fas ligand (FASL) pathway.”
• Diversity, Mechanisms and Significance of Macrophage Plasticity (2019, background): “Collectively, macrophages are a major component of the immunosuppressive milieu of different murine and human tumors and major drivers of checkpoint blockade, even in tumors such as Hodgkin’s lymphoma, in which PD-L1 amplification occurs in neoplastic cells (141).”
• Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells (2020, methodology): “To delineate putative mechanisms in the BrM TME that may drive these alterations, we probed the RNA-seq data from CD45 cells, TAMs, and T cells (Figure 7E) for expression of activating and inhibitory immunomodulatory signals (Wei et al., 2018).”